Search results for "International agencies"

showing 10 items of 19 documents

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

2016

International audience; Evidence from a small number of studies suggests that longer telomere length measured in peripheral leukocytes is associated with an increased risk of non-Hodgkin lymphoma (NHL). However, these studies may be biased by reverse causation, confounded by unmeasured environmental exposures and might miss time points for which prospective telomere measurement would best reveal a relationship between telomere length and NHL risk. We performed an analysis of genetically inferred telomere length and NHL risk in a study of 10 102 NHL cases of the four most common B-cell histologic types and 9562 controls using a genetic risk score (GRS) comprising nine telomere length-associa…

0301 basic medicineSerumMaleLymphomaanalysisChronic lymphocytic leukemiaFollicular lymphomaGlobal Health[ SDV.CAN ] Life Sciences [q-bio]/Cancerimmunologysurgery0302 clinical medicineEndocrinologyimmune system diseasessingle nucleotide polymorphismGermanyhemic and lymphatic diseasesLondon80 and overOdds RatiogeneticsProspective StudiesB-cell lymphomaAssociation Studies ArticleGenetics (clinical)Aged 80 and overeducation.field_of_studytelomereGenomeLeukemiaAge FactorsGeneral MedicineEnvironmental exposureGenomicsMiddle Agedb-cell lymphomasmall cell lymphomaItaly030220 oncology & carcinogenesisMedicineepidemiologyFemaleFranceRisk of B-cell lymphoma subtypesRiskAdultCanadaChinaLymphoma B-CellGenotypeAdolescentleukocytesetiologyPopulationPopulation[SDV.CAN]Life Sciences [q-bio]/CancerBiologyEnvironmentRisk AssessmentmethodsTime03 medical and health sciencesmedicineHumansFamilyGenetic Predisposition to DiseaseeducationMolecular BiologyAllelesOccupational HealthGenetic Association StudiesAgedB-CellInternational AgenciesOdds ratioEnvironmental Exposuremedicine.diseaseTelomereNon-Hodgkin's lymphoma030104 developmental biologyImmunologyphysiologyChronic DiseasepathologyLaboratoriesmetabolism
researchProduct

Development of certified environmental management in hospital and outpatient haemodialysis units

2015

Antecedentes: El impacto ambiental de la hemodiálisis es destacado. Está destacando la actividad en este sentido incluso a nivel bibliográfico. Los sistemas de gestión medioambiental (SGMA) voluntarios, Environmental Management and Auditing System (EMAS) e International Organization for Standardization (ISO 14001), son instrumentos destacados para la protección medioambiental junto a legislación, impuestos y beneficios fiscales. Objetivos: Conocer el grado de implantación de los SGMA en las unidades de hemodiálisis hospitalarias y ambulatorias del Sistema Nacional de Salud español, para disponer de un grupo de centros de referencia en gestión medioambiental en esta actividad sanitaria. Méto…

Conservation of Natural ResourcesCertificationOutpatient clinicEnvironmentlcsh:RC870-923GestiónAmbulatory Care FacilitiesEnvironmentalHospitalRenal DialysisClínica ambulatoriaAtención sanitariaRegistriesNefrologíaInternetHealth PolicyHealthcareInternational AgenciesDiálisislcsh:Diseases of the genitourinary system. UrologyManagementHaemodialysisSpainNephrologyWasteMedio ambienteManagement AuditGuideline AdherenceEnvironmental PollutionResiduoHospital UnitsNefrología (English Edition)
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct

Classification or non-classification of substances with positive tumor findings in animal studies: Guidance by the German MAK commission

2019

One of the important tasks of the German Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (known as the MAK Commission) is in the evaluation of a potential for carcinogenicity of hazardous substances at the workplace. Often, this evaluation is critically based on data on carcinogenic responses seen in animal studies and, if positive tumor responses have been observed, this will mostly lead to a classification of the substance under investigation into one of the classes for carcinogens. However, there are cases where it can be demonstrated with a very high degree of confidence that the tumor findings in the experimental animals are not relevant…

Life sciences; biologyApplied psychologyMechanism of tumorigenesisGuidelines as TopicCommissionAir Pollutants Occupational010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentGerman03 medical and health sciences0302 clinical medicineGovernment AgenciesSpecies SpecificityTumor Findingsddc:570GermanyNeoplasmsOccupational ExposureAnimalsHumansHuman relevance0105 earth and related environmental sciencesCarcinogenicitySpecies-specific tumorsMaximally tolerated doseInternational AgenciesGeneral Medicinelanguage.human_languageOccupational DiseasesCategorizationlanguageCarcinogensDegree of confidencePsychologyAnimal tumor studiesOrgan-specific tumors
researchProduct

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

2013

Human papillomavirus (HPV) 58 accounts for a notable proportion of cervical cancers in East Asia and parts of Latin America, but it is uncommon elsewhere. The reason for such ethnogeographical predilection is unknown. In our study, nucleotide sequences of E6 and E7 genes of 401 HPV58 isolates collected from 15 countries/cities across four continents were examined. Phylogenetic relationship, geographical distribution and risk association of nucleotide sequence variations were analyzed. We found that the E6 genes of HPV58 variants were more conserved than E7. Thus, E6 is a more appropriate target for type-specific detection, whereas E7 is more appropriate for strain differentiation. The frequ…

Cancer ResearchSettore MED/07 - Microbiologia E Microbiologia Clinicacervical cancerSettore MED/06 - Oncologia MedicaPapillomavirus E7 ProteinsUterine Cervical NeoplasmsCervix UteriphylogenyPolymerase Chain ReactionViralPapillomaviridaePapillomaviridaePhylogenyCancerOncogene ProteinsCervical cancerGeneticsTumorGeographybiologyNucleic acid sequenceDNA NeoplasmPrognosisInfectious DiseasesOncologyHIV/AIDSFemaleHPVhuman papillomavirus type 58 E6 and E7 sequence variationsOncology and CarcinogenesisCervical intraepithelial neoplasiaRisk AssessmentArticleVaccine Relatedoncogenic riskClinical ResearchPhylogeneticsGenetic variationGeneticsBiomarkers TumormedicineHumansOncology & CarcinogenesisGenePreventionPapillomavirus InfectionsGenetic VariationInternational AgenciesDNAOncogene Proteins ViralOdds ratioUterine Cervical Dysplasiamedicine.diseasebiology.organism_classificationVirologyvariantNeoplasmSexually Transmitted InfectionsCapsid ProteinsBiomarkersFollow-Up Studies
researchProduct

International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein–Coupled Receptors

2015

The Adhesion family forms a large branch of the pharmacologically important superfamily of G protein-coupled receptors (GPCRs). As Adhesion GPCRs increasingly receive attention from a wide spectrum of biomedical fields, the Adhesion GPCR Consortium, together with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification, proposes a unified nomenclature for Adhesion GPCRs. The new names have ADGR as common dominator followed by a letter and a number to denote each subfamily and subtype, respectively. The new names, with old and alternative names within parentheses, are: ADGRA1 (GPR123), ADGRA2 (GPR124), ADGRA3 (GPR125), ADGRB1 (BAI1…

Models MolecularSocieties ScientificSubfamilyComputational biologyBiologyGPR110PharmacologyLigandsGPR113Second Messenger SystemsReceptors G-Protein-CoupledCell MovementTerminology as TopicCell AdhesionCyclic AMPAnimalsHumansProtein IsoformsReceptorNomenclatureG protein-coupled receptorPharmacologyCell MembraneInternational AgenciesAdhesionQPGPR56Pharmacology ClinicalIUPHAR Nomenclature ReportsMolecular MedicineQP517Cell Adhesion MoleculesSignal TransductionPharmacological Reviews
researchProduct

Testing the validity of the International Atomic Energy Agency (IAEA) safety culture model

2012

This paper takes the first steps to empirically validate the widely used model of safety culture of the International Atomic Energy Agency (IAEA), composed of five dimensions, further specified by 37 attributes. To do so, three independent and complementary studies are presented. First, 290 students serve to collect evidence about the face validity of the model. Second, 48 experts in organizational behavior judge its content validity. And third, 468 workers in a Spanish nuclear power plant help to reveal how closely the theoretical five-dimensional model can be replicated. Our findings suggest that several attributes of the model may not be related to their corresponding dimensions. Accordi…

AdultMaleEngineeringAdolescentOperations researchPoison controlHuman Factors and ErgonomicsOCCUPATIONAL SAFETYComputer securitycomputer.software_genrelaw.inventionYoung AdultATOMIC PROCESSESlawSurveys and QuestionnairesNuclear power plantAgency (sociology)Content validityHumansSafety cultureSafety Risk Reliability and QualityFace validityModels Statisticalbusiness.industryAtomic energyPublic Health Environmental and Occupational HealthInternational AgenciesReproducibility of ResultsMiddle AgedNuclear EnergyOrganizational CultureSpainOrganizational behaviorModels OrganizationalSafety cultureFemaleSafetyFactor Analysis Statisticalbusinesscomputer
researchProduct

La Asociación Europea contra la Poliomielitis y los programas europeos de vacunación

2012

La búsqueda de una respuesta europea al problema planteado por los brotes epidémicos de poliomielitis en las décadas centrales del siglo XX, desembocó en la creación de un organismo nuevo, la Asociación Europea contra la Poliomielitis en 1951. Los mecanismos de funcionamiento interno y las conexiones internacionales de dicha Asociación fueron subsidiarios de un determinado contexto socio-político que propiciaba este tipo de consorcios. Como muestra este trabajo, su labor en los dieciocho años de existencia fue decisiva para la articulación y el éxito alcanzado por las políticas sanitarias nacionales de inmunización masiva frente a la enfermedad.

Public healthorganismos sanitarios internacionalesInternational agenciesPolio vaccinationAsociación Europea contra la PoliomielitisVacunació antipoliomielíticaEuropean Association against Poliomyelitis20th centurypoliomielitisGeneral MedicineOrganització Mundial de la Salut (OMS)World Health Organization (WHO)Política sanitàriaSegle XXpolítica sanitariaOrganismes sanitaris internacionalsHistory and Philosophy of ScienceOrganización Mundial de la Salud (OMS)World Health Organisation (WHO)vacunación antipoliomielíticasiglo XXPoliomyelitis
researchProduct

Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations

2007

Policy Forum. Competing interests: ER has received research grants from Daiichi, Bayer, and Theravance and has served as a consultant to Pfizer, Theravance, Bayer, Wyeth, Rosetta, and BiondVax. Summary Points Brucellosis remains the commonest anthropozoonosis worldwide, and its treatment remains complex, requiring protracted administration of more than one antibiotic. In November 2006, a consensus meeting aimed at reaching a common specialist statement on the treatment of brucellosis was held in Ioannina, Greece under the auspices of the International Society of Chemotherapy and the Institute of Continuing Medical Education of Ioannina. The author panel suggests that the optimal treatment o…

:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Veterinary medicine:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Streptomycin [Medical Subject Headings]:Phenomena and Processes::Microbiological Phenomena::Drug Resistance Microbial [Medical Subject Headings]DiseaseGlobal Health:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Health Care::Population Characteristics::Health::World Health [Medical Subject Headings]Terminología como AsuntoBrucellosi:Organisms::Eukaryota::Animals [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::International Agencies::United Nations::World Health Organization [Medical Subject Headings]Policy ForumMedicine in Developing CountriesGentamicinasDrug Resistance MicrobialBrucelosisAdhesión a DirectrizGeneral MedicineHumanosDrug CombinationsAntibacterianosDoxycyclineStreptomycinEstreptomicinaMedicine:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds with 4 or More Rings::Rifamycins::Rifampin [Medical Subject Headings]Drug Therapy CombinationGuideline AdherenceRifampinFluoroquinolonesSalud Mundialmedicine.medical_specialtyEfficacyResultado del TratamientoInvestigación BiomédicaRecurrenciaTherapeuticsWorld Health OrganizationMicrobiologyAntibiotic resistanceTerminology as Topic:Disciplines and Occupations::Social Sciences::Internationality::International Cooperation::Developing Countries [Medical Subject Headings]HumansMedical journalIntensive care medicineDeveloping Countries:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Pyrimidines::Trimethoprim::Trimethoprim-Sulfamethoxazole Combination [Medical Subject Headings]medicine.diseaseCotrimoxazoleAnimalesQuimioterapia:Humanities::Humanities::History::History Modern 1601-::History 21st Century [Medical Subject Headings]GentamicinsBrucel·losiBiomedical ResearchCommunicable diseases:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 2-Ring::Quinolines::Quinolones::Fluoroquinolones [Medical Subject Headings]Human diseaseRecurrence:Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations [Medical Subject Headings]:Information Science::Information Science::Communication::Language::Linguistics::Terminology as Topic [Medical Subject Headings]biologyIraqi patientsRMetaanalysis:Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Brucellosis [Medical Subject Headings]Historia del Siglo XXIAnti-Bacterial AgentsCombinación Trimetoprim-SulfametoxazolTreatment OutcomeInfectious Diseases:Disciplines and Occupations::Natural Science Disciplines::Science::Research::Biomedical Research [Medical Subject Headings]:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Tetracyclines::Doxycycline [Medical Subject Headings]Fluoroquinolonas:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [Medical Subject Headings]:Chemicals and Drugs::Carbohydrates::Glycosides::Aminoglycosides::Gentamicins [Medical Subject Headings]Países en Desarrollo:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy Combination [Medical Subject Headings]BrucellaHistory 21st CenturyBrucellosisWorld healthTrimethoprim Sulfamethoxazole Drug CombinationmedicineAnimals:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]Resistencia a Medicamentosbusiness.industryOrganización Mundial de la SaludBrucellosisMalalties infecciosesTerapèuticabiology.organism_classificationCombinación de MedicamentosDoxiciclinaTherapybusinessBrucella melitensisPLoS Medicine
researchProduct

Tumor necrosis factor (TNF) and lymphotoxin-a (LTA) polymorphisms and risk of non-hodgkin lymphoma in the interLymph consortium

2010

In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF -308G>A (rs1800629), lymphotoxin-alpha (LTA) 252A>G (rs909253), IL10 -3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-…

MaleEpidemiologyTNFGastroenterology0302 clinical medicineRisk Factorsimmune system diseaseshemic and lymphatic diseasesAged 80 and over0303 health scienceseducation.field_of_studyLymphoma Non-Hodgkinnon-Hodgkin lymphomaMiddle Aged3. Good healthInterleukin-10EuropeLTA030220 oncology & carcinogenesisFemaleLymphotoxin alphaAdultmedicine.medical_specialtyCanadaAdolescentTumor necrosis factorMeta- and Pooled AnalysesPopulationPolymorphism Single NucleotideWhite People03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Predisposition to Diseaseeducation030304 developmental biologyAgedMycosis fungoidesbusiness.industryTumor Necrosis Factor-alphaAustraliaInternational AgenciesInterLymph ConsortiumOdds ratiomedicine.diseaseUnited StatesNon-Hodgkin's lymphomaLymphomaCase-Control StudiesImmunologyMantle cell lymphomalymphotoxin-alphabusinessDiffuse large B-cell lymphoma
researchProduct